Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome
Sponsor: Future University in Egypt
Summary
In PCOS (Polycystic Ovary Syndrome), studies have found impaired incretin secretion and activity, particularly in overweight/obese individuals. Conflicting results exist regarding glucagon-like peptide-1(GLP-1) levels in PCOS patients, with studies reporting reduced, normal, or increased levels. Incretin-based therapy has been suggested as a potential treatment to reverse prediabetes risk by preserving β-cell function in patients with impaired fasting glucose(IFG and impaired glucose tolerance(IGT). The study aims to compare the efficacy of Dapagliflozin to Metformin for the treatment of non-diabetic patients with polycystic ovary syndrome (PCOS).
Official title: Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome: A Prospective Comparative Randomized Blinded Trial.
Key Details
Gender
FEMALE
Age Range
18 Years - 40 Years
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2024-09-02
Completion Date
2025-01
Last Updated
2024-10-22
Healthy Volunteers
No
Conditions
Interventions
Dapagliflozin
oral Dapagliflozin
Metformin
oral metformin
Locations (1)
October 6 University Hospital
Giza, Egypt